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1. INTRODUCTION {#ags312292-sec-0005}
===============

Left hepatic trisectionectomy (LHT) was first described in detail by Starzl and colleagues as a left trisegmentectomy in 1982, and then as an extended left hepatectomy by Blumgart et al in 1993.[1](#ags312292-bib-0001){ref-type="ref"}, [2](#ags312292-bib-0002){ref-type="ref"} The designation LHT was adopted following the International Hepato‐Pancreato‐Biliary Association Brisbane 2000 consensus statement on the nomenclature of liver anatomy and resection. LHT is defined as excision of Couinaud liver segments 2, 3, 4, 5 and 8, with or without segment 1.[3](#ags312292-bib-0003){ref-type="ref"} Despite improvements in surgical techniques and perioperative patient management, only a few papers have reported outcomes of LHT in more than 10 patients.[4](#ags312292-bib-0004){ref-type="ref"}, [5](#ags312292-bib-0005){ref-type="ref"}, [6](#ags312292-bib-0006){ref-type="ref"}, [7](#ags312292-bib-0007){ref-type="ref"}, [8](#ags312292-bib-0008){ref-type="ref"} Morbidity and mortality after LHT is higher than for other hepatectomies, and this procedure is reserved for patients with a significant tumor burden and an otherwise dismal prognosis. The high morbidity rate is attributable mainly to the aggressive nature of the disease being treated, but may also be related to the extent of liver volume resected, estimated to be as high as 80 per cent.[2](#ags312292-bib-0002){ref-type="ref"} In 2005, the Leeds group reported long‐term outcomes of LHT in 70 consecutive patients.[4](#ags312292-bib-0004){ref-type="ref"} Morbidity rate was high, but the potential for cure supported an aggressive surgical resection policy where other treatment options had been exhausted. In 2016, the same group described changes in surgical practice over time, and analyzed the short‐ and long‐term outcomes of LHT for hepatobiliary malignancy, in order to identify factors associated with morbidity and mortality in the modern era.[9](#ags312292-bib-0009){ref-type="ref"}

Right hepatic trisectionectomy (RHT) was first described by Lortat‐Jacob, Robert and Henry as right lobectomy in 1952.[10](#ags312292-bib-0010){ref-type="ref"} This operation has had a number of different names, but, until recently, it has been most commonly known as right trisegmentectomy. The designation RHT was adopted following the International Hepato‐Pancreato‐Biliary Association Brisbane 2000 consensus statement on the nomenclature of liver anatomy and resection.[3](#ags312292-bib-0003){ref-type="ref"}, [11](#ags312292-bib-0011){ref-type="ref"} This procedure requires excision of segments 4, 5, 6, 7 and 8 ± 1 and it also remains one of the most challenging major hepatectomies. Despite improvements in surgical technique and perioperative critical management, perioperative morbidity remains high and only a few hepatobiliary centers worldwide have reported their experience.[12](#ags312292-bib-0012){ref-type="ref"}, [13](#ags312292-bib-0013){ref-type="ref"}

Modifications of LHT and RHT by in‐contiguity and non‐anatomical extension and repeat liver resection after LHT or RHT are also rarely reported.[14](#ags312292-bib-0014){ref-type="ref"}, [15](#ags312292-bib-0015){ref-type="ref"}

The role of these technically demanding and extensive resections in contemporary hepatobiliary practice is established for primary liver cancers and for those tumors with no significant neoadjuvant strategies, but it is also changing as new treatments emerge. This is particularly true for patients with colorectal liver metastases (CRLM), and it is likely that this trend will be followed for other HPB malignancies as more effective preoperative strategies are developed. Emerging data for intrahepatic cholangiocarcinoma, for example, is encouraging.[16](#ags312292-bib-0016){ref-type="ref"}, [17](#ags312292-bib-0017){ref-type="ref"}, [18](#ags312292-bib-0018){ref-type="ref"}, [19](#ags312292-bib-0019){ref-type="ref"}

For patients with CRLM, despite the lack of compelling data for most patients, there has been a paradigm shift in the oncological assessment of patients and the use of neoadjuvant and "downstaging" strategies before resection. This has been combined with a sensible development of surgical strategies aimed at parenchymal preservation, along with new developments in liver surgery such as multistage resection as a classical two‐stage approach (TSH) or associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). In the classical two‐stage approach, portal vein embolization (PVE) or portal vein ligation (PVL) is carried out to stimulate hypertrophy in the planned future liver remnant, along with resection of tumors from the planned future liver remnant (FLR). After an interval of 4‐8 weeks, with adequate hypertrophy of the FLR, the definitive resection is carried out.[20](#ags312292-bib-0020){ref-type="ref"} Besides PVL/PVE, the first step in ALPPS includes at least a 50% transection of liver parenchyma.[21](#ags312292-bib-0021){ref-type="ref"} By this modification, ALPPS seems to be able to accelerate liver growth of the FLR and to shorten the interstage interval.[22](#ags312292-bib-0022){ref-type="ref"}, [23](#ags312292-bib-0023){ref-type="ref"} A recent Scandinavian randomized controlled trial has shown the benefits of ALPPS in providing a higher resection rate compared to the classical two‐stage procedure, with comparable margins, complications and short‐term mortality.[24](#ags312292-bib-0024){ref-type="ref"}

However, besides the evolvement of these promising strategies, there remains a place for up‐front major resection for many patients. In the light of this trend, we have reviewed in detail a 22‐year single‐center experience of RHT for CRLM and evaluated factors affecting morbidity and survival in order to provide a critical appraisal for the role of RHT for CRLM in order to add these data to our previous work on LHT.

2. METHODS {#ags312292-sec-0006}
==========

2.1. Study design {#ags312292-sec-0007}
-----------------

Patients undergoing RHT between January 1993 and December 2014 were identified from a prospectively maintained database at a single institution. Additional data from the database included radiological investigations and interventions, presence or absence of jaundice, extent of surgical resection, duration of operation, requirement for transfusion of blood or blood products, need for Pringle maneuver or total vascular exclusion, additional surgery (lymphadenectomy, extrahepatic bile duct excision with reconstruction, or vascular reconstruction), histopathological diagnosis, size and distribution of tumors, perioperative morbidity and mortality, and long‐term disease‐free and disease‐specific survival. This work has been reported in line with the PROCESS criteria.[25](#ags312292-bib-0025){ref-type="ref"}

All patients undergoing liver resection were offered adjuvant chemotherapy according to guidelines unless they had received adjuvant therapy following their colonic resection within the past 12 months. However, detailed data on adjuvant chemotherapy after colorectal and hepatic surgery were not routinely collected in the database owing to the large number of patients presenting from a wide geographical area of referring hospitals using chemotherapy. In 12 patients, neoadjuvant chemotherapy was used as either a downsizing technique or as a "test of time approach."

2.2. Preoperative evaluation {#ags312292-sec-0008}
----------------------------

Preoperative radiological assessment in all patients included thoracic, abdominal and pelvic computed tomography (CT), and magnetic resonance imaging (MRI) of the liver. The investigations were reviewed in a multidisciplinary team meeting to discuss and define the extent of resection. In selected cases, positron emission tomography CT (PET‐CT) was used. From 2007, PVE was used when the future liver remnant was estimated to be \<20% and was carried out 3 to 4 weeks before scheduled liver resection, but no formal volumetry studies have been done in our center.

2.3. Perioperative care {#ags312292-sec-0009}
-----------------------

Techniques of RHT and extensions of RHT have been described previously.[14](#ags312292-bib-0014){ref-type="ref"}, [26](#ags312292-bib-0026){ref-type="ref"}, [27](#ags312292-bib-0027){ref-type="ref"} Intraoperative ultrasound was carried out in all patients to identify any additional lesions in segments 2 and 3, and their relation to the left portal structures and hepatic veins. All liver transections were carried out using a Cavitron ultrasonic surgical aspirator (CUSA). Pringle\'s maneuver was applied in selected patients to reduce blood loss and total hepatic vascular exclusion (TVE) (portal triad and hepatic vein or inferior vena cava \[IVC\] clamping) was used when necessary for tumors located at the hepatocaval confluence. Intraoperative allogeneic red blood cells (ARBC) and fresh frozen plasma were transfused at the discretion of the anesthesiologist. ARBC were also transfused postoperatively if the hemoglobin level fell to \<8.0 g/dL in the absence of cardiac disease and \<10.0 g/dL for patients with risk factors for cardiac disease according to our unit policy. No patients received autologous blood transfusion.

2.4. Morbidity and mortality {#ags312292-sec-0010}
----------------------------

Details of complications were obtained from the database and, where necessary, from the patient notes and graded according to the validated Clavien‐Dindo classification system.[28](#ags312292-bib-0028){ref-type="ref"} Postoperative liver failure was defined according to the International Study Group of Liver Surgery.[29](#ags312292-bib-0029){ref-type="ref"} Postoperative mortality was defined by the occurrence of death within 90 days of surgery or at any time during postoperative hospital stay.

2.5. Histopathological evaluation {#ags312292-sec-0011}
---------------------------------

Pathological reports were reviewed to determine tumor histological grade, margin status, and histological abnormalities in the non‐tumor‐bearing liver (NTBL). A tumor‐free resection margin of less than 1 mm was classified as (R1), and 1 mm or more was classified as (R0).[30](#ags312292-bib-0030){ref-type="ref"} In relation to NTBL, liver steatosis was defined as diffuse accumulation of fat droplets affecting \>5% of hepatocytes.[31](#ags312292-bib-0031){ref-type="ref"} Fibrosis was scored according to the Metavir score, and defined as the presence of portal fibrosis with/without septa, numerous septa, or cirrhosis.[32](#ags312292-bib-0032){ref-type="ref"} Sinusoidal injury was graded and defined as the presence of centrilobular involvement beyond one‐third of the lobular area.[33](#ags312292-bib-0033){ref-type="ref"} These findings in NTBL were defined as parenchymal liver damage in the present study.

2.6. Follow up {#ags312292-sec-0012}
--------------

All patients were followed up regularly at the outpatient clinic at 1, 3, 6 and 12 months in the first year, 18 and 24 months in the second year, and yearly thereafter if the patient remained disease‐free. Follow up included clinical examination and assessment of tumor markers (carcinoembryonic antigen \[CEA\], cancer antigen \[CA\]19‐9). Surveillance imaging included CT scans of the chest, abdomen, and pelvis at 3, 6, 12, 18 and 24 months, annually to 5 years and again at 7 and 10 years. MRI and PET‐CT were carried out if recurrence was suspected in routine follow up.

2.7. Survival {#ags312292-sec-0013}
-------------

Disease‐free survival (DFS) was defined as the time from operation to the first documented disease recurrence on imaging. Disease‐specific survival (DSS) was defined as the time from operation to the time of death as a result of recurrence or the most recent follow‐up time. Patients dying of other causes with no evidence of recurrence were censored. In this study of effect on long‐term disease and survival, patients with death within 90 days of operation were excluded.

2.8. Statistical analysis {#ags312292-sec-0014}
-------------------------

Continuous variables were expressed as median and interquartile range. To consider changes over the study period, patients were divided into three periods based on time interval of treatment: time period 1, 1993‐2000; time period 2, 2001‐2007; time period 3, 2008‐2014. The Kruskal‐Wallis test was used for continuous variables and the Pearson chi‐squared test or Fisher\'s exact test, where appropriate, for categorical variables. Univariate analysis for postoperative complications was carried out using the Pearson chi‐squared test or Fisher\'s exact test where appropriate. Multivariate analysis was carried out by Cox regression (stepwise forward model) for variables shown to have a significant influence on postoperative morbidity, 90‐day mortality, and disease‐specific overall and disease‐free survival in the univariate analysis. Date of last follow up was February 2015. All statistical analyses were done using SPSS for Windows/MacTM version 20.0 (IBM), and statistical significance was taken at the 5% level.

3. RESULTS {#ags312292-sec-0015}
==========

3.1. Patient characteristics {#ags312292-sec-0016}
----------------------------

Between January 1993 and December 2014, a total of 3946 liver resections were carried out at this single UK center. Of these, 399 (10%) patients underwent RHT, of whom 188 (47%) patients (hepatocellular carcinoma, n = 35 (18.5%); non CRLM, n = 31 (16.5%); hilar cholangiocarcinoma, n = 36 (19%); intrahepatic cholangiocarcinoma, n = 20 (11%); gallbladder cancer, n = 16 (8.5%); benign liver tumor, n = 15 (8%); other malignant liver tumor, n = 6 (3.2%); other benign bile duct disease, n = 5 (2.7%); RHT as part of auxiliary orthotopic liver transplantation, n = 24 (12.8%) were excluded.

A total of 211 patients were included: 126 (60%) male, 85 (40%) female with a median age of 62 years (range, 25‐85). All of the 211 patients included in this analysis underwent RHT for CRLM.

3.2. Tumor characteristics {#ags312292-sec-0017}
--------------------------

In the cohort, 49 patients (23%) had solitary tumors and median size of the largest tumor was 50 (range 8‐410) mm. Neoadjuvant chemotherapy was given to 12 (5.6%) patients. In 13 (6%) patients, portal vein embolization was done before the actual surgery. Twenty‐five (12%) and 80 (38%) patients underwent concomitant segment (S)1 and/or S2/S3 metastectomy, respectively. Three (1.4%) patients underwent ex vivo resection. Thirty‐two (15%) patients required additional organ resection: in 19 (59%) patients, the diaphragm had to be resected, followed by large bowel n = 8 (25%) and others n = 5 (16%). In 72 (34%) of the patients, some form of parenchymal liver damage was noted: 57 (27%), six (3%) and 18 (9%) with steatosis, fibrosis and sinusoidal obstructive syndrome, respectively. Some patients had two or three duplicate types of liver damage.

3.3. Short‐ and long‐term outcomes, morbidity and mortality {#ags312292-sec-0018}
-----------------------------------------------------------

Forty‐four patients (21%) received a blood transfusion, with a median ARBC transfusion of 4 units (range 1‐40). Median hospital stay was 10 days (range, 4‐139 days). Of the 211 patients who underwent RHT for CRLM, 85 (40.3%) had postoperative complications as described in Table [1](#ags312292-tbl-0001){ref-type="table"}. Thirty‐eight (18%) patients had more than two postoperative complications. Re‐laparotomy was carried out in 19 (9%) patients of the cohort, the main reason being intra‐abdominal bleeding n = 9 (47.4%). Four (21%) of the patients who underwent re‐laparotomy died in hospital.

###### 

Postoperative outcomes after right trisectionectomy for colorectal liver metastases

  Outcomes                                                                     n (%)
  ---------------------------------------------------------------------------- ------------
  Overall morbidity                                                            85 (40.3)
  Grade I                                                                      10 (4.7)
  Grade II                                                                     21 (10.0)
  Grade IIIa                                                                   11 (5.2)
  Grade IIIb                                                                   13 (6.2)
  Grade IVa                                                                    7 (3.3)
  Grade IVb                                                                    8 (3.8)
  Grade V (in‐hospital death)                                                  15 (7.1)
  Median hospital stay, days (range)[a](#ags312292-note-0001){ref-type="fn"}   10 (4‐139)
  90‐d mortality                                                               16 (7.6)
  Morbidity details[b](#ags312292-note-0002){ref-type="fn"}                    
  Transient liver failure                                                      25 (11.8)
  Wound infection                                                              12 (5.7)
  Bile leak                                                                    12 (5.7)
  Sepsis                                                                       11 (5.2)
  Intra‐abdominal bleeding                                                     11 (5.2)
  Renal failure                                                                9 (4.3)
  Pneumonia                                                                    8 (3.8)
  Cardiac events[c](#ags312292-note-0003){ref-type="fn"}                       6 (2.8)
  Gastrointestinal bleeding                                                    6 (2.8)
  Intra‐abdominal fluid collection                                             6 (2.8)
  Wound dehiscence                                                             3 (1.4)
  Intra‐abdominal abscess                                                      2 (0.9)
  Bowel obstruction                                                            2 (0.9)
  Pulmonary embolism                                                           2 (0.9)
  Portal vein thrombosis                                                       2 (0.9)
  Minor non‐specific complications                                             9 (4.3)

Excluding 15 patients who died in hospital.

38 patients had two or more complications.

Including myocardial infarction, congestive heart failure, and arrhythmia.

John Wiley & Sons, Ltd

Of the whole cohort, 15 (7.1%) patients died in hospital. One other patient (0.5%) died within 90 days following surgery. Therefore, 16 patients (7.6%) died within 90 days. Among these 16 patients, main causes for mortality were as follows: seven (44%) patients died from multi‐organ failure; three (19%) patients died as a result of gastrointestinal bleeding; two (13%) due to acute myocardial infarction; one (6%) as a result of pneumonia or intra‐abdominal abscess (n = 1, 6%); massive abdominal bleeding (n = 1, 6%) in hospital; and unknown cause (n = 1, 6%) after discharge. The 211 included patients were further divided into three time periods where 70 patients were included in the first period, 70 patients in the second period and 71 patients in the third period, respectively. With increasing experience at our center we were able to decrease 90‐day mortality from 12.8% to 7.1% and 2.8% accordingly. These differences were not significant.

Univariate analysis for morbidity showed that other organ resection (*P* = .017) and ARBC transfusion (*P* = .012) were markers for poor outcome. Both variables were also found to be independent predictors for morbidity in multivariate analysis (odds ratio \[OR\] for other organ resection = 2.27; 95% confidence interval \[CI\], 1.04‐4.95; *P* = .040) and ARBC transfusion (OR = 2.16; 95% CI, 1.09‐4.30; *P* = .028). Notably, parenchymal liver damage in NTBL did not significantly impact morbidity, disease recurrence and survival (Table [2](#ags312292-tbl-0002){ref-type="table"}). Median follow up was 29.8 months (range, 0 to 255.7 months) in the entire cohort. DSS rates at 1, 3, 5, and 10 years after RHT were 89.7%, 55.7%, 33.7%, and 22.4%, respectively, with a median DSS of 39.7 months. One‐, 3‐, and 5‐year DFS were 58.7%, 26.6%, and 20.9%, respectively, with median DFS time of 13.3 months. Significant predictors of decreased DFS in univariate analysis were preoperative PVE (*P* = .030), preoperative chemotherapy (*P* = .029), multiple tumors (*P* \< .001), caudate lobectomy (*P* = .034), additional metastectomy from segment 2 and/or 3 (*P* \< .001), other organ resection (*P* = .015), TVE (*P* = .001), and R1 resection (*P* \< .001). In multivariate analysis, multiple tumors (risk ratio \[RR\] = 1.99; 95% CI, 1.24‐3.20; *P* = .005), TVE (RR = 3.05; 95% CI, 1.42‐6.57; *P* = .004), and R1 resection (RR = 1.60; 95% CI, 1.11‐2.29; *P* = .012) were independent prognostic factors for DFS (Table [3](#ags312292-tbl-0003){ref-type="table"}). Likewise, for DSS, preoperative PVE (*P* = .009), preoperative chemotherapy (*P* = .043), multiple tumors (*P* \< .001), combined caudate lobectomy (*P* = .042), partial resection of segment 2 and/or 3 (*P* = .023), TVE (*P* = .009), and R1 resection (*P* \< .001) were found to be significant factors. In multivariate analysis, multiple tumors (RR = 2.95; 95% CI, 1.68‐5.20; *P* \< .001), TVE (RR = 3.77; 95% CI, 1.73‐8.20; *P* = .001), and R1 resection (RR = 1.92; 95% CI, 1.31‐2.81; *P* \< .001) were independent prognostic factors for DSS as with DFS (Table [4](#ags312292-tbl-0004){ref-type="table"}).

###### 

Univariate and multivariate analyses of variables affecting morbidity after right trisectionectomy

  Variables                                                    Total   Morbidity (%)   Univariate analysis   Multivariate analysis                                              
  ------------------------------------------------------------ ------- --------------- --------------------- ----------------------------------------------- ------------------ -----------------------------------------------
  Preoperative variables                                                                                                                                                        
  Gender                                                                                                                                                                        
  Female                                                       85      32 (37.6)       1.20 (0.68‐2.11)      .521                                                                
  Male                                                         126     53 (42.1)                                                                                                
  Age                                                                                                                                                                           
  ≤70 y                                                        165     63 (38.2)       1.48 (0.77‐2.87)      .238                                                                
  \>70 y                                                       46      22 (47.8)                                                                                                
  Preoperative PVE                                                                                                                                                              
  No PVE                                                       198     79 (39.9)       1.29 (0.42‐3.99)      .656                                                                
  PVE                                                          13      6 (46.2)                                                                                                 
  Preoperative chemotherapy                                                                                                                                                     
  No                                                           122     49 (40.2)       1.01 (0.58‐1.77)      .967                                                                
  Yes                                                          89      36 (40.4)                                                                                                
  Size of largest tumor                                                                                                                                                         
  ≤100 mm                                                      170     73 (42.9)       0.55 (0.26‐1.15)      .806                                                                
  \>100 mm                                                     41      12 (29.3)                                                                                                
  No. of tumors                                                                                                                                                                 
  Solitary                                                     49      19 (38.8)       1.09 (0.56‐2.09)      .806                                                                
  Multiple                                                     162     66 (40.7)                                                                                                
  Parenchymal liver damage^a^                                                                                                                                                   
  No                                                           139     58 (41.7)       0.84 (0.47‐1.50)      .553                                                                
  Yes                                                          72      27 (37.5)                                                                                                
  Intra‐ and postoperative variables                                                                                                                                            
  S1 resection                                                                                                                                                                  
  No                                                           186     71 (38.2)       2.06 (0.89‐4.79)      .088                                                                
  Yes                                                          25      14 (56.0)                                                                                                
  S2/3 partial resection                                                                                                                                                        
  No                                                           131     57 (43.5)       0.70 (0.39‐1.24)      .221                                                                
  Yes                                                          80      28 (35.0)                                                                                                
  Other organ resection                                                                                                                                                         
  No                                                           179     66 (36.9)       2.50 (1.16‐5.39)      .017[\*](#ags312292-note-0007){ref-type="fn"}   2.27 (1.04‐4.95)   .040[\*](#ags312292-note-0007){ref-type="fn"}
  Yes                                                          32      19 (59.4)                                                                                                
  Vascular resection[a](#ags312292-note-0006){ref-type="fn"}                                                                                                                    
  No                                                           196     76 (38.8)       2.37 (0.81‐6.92)      .106                                                                
  Yes                                                          15      9 (60.0)                                                                                                 
  Pringle\'s maneuver                                                                                                                                                           
  No                                                           74      30 (40.5)       0.98 (0.55‐1.75)      .956                                                                
  Yes                                                          137     55 (40.1)                                                                                                
  Total hepatic vascular exclusion                                                                                                                                              
  No                                                           197     77 (39.1)       2.08 (0.69‐6.22)      .183                                                                
  Yes                                                          14      8 (57.1)                                                                                                 
  Allogenic red blood cell transfusion                                                                                                                                          
  No                                                           167     60 (35.9)       2.35 (1.20‐4.61)      .012[\*](#ags312292-note-0007){ref-type="fn"}   2.16 (1.09‐4.30)   .028[\*](#ags312292-note-0007){ref-type="fn"}
  Yes                                                          44      25 (56.8)                                                                                                
  Fresh frozen plasma transfusion                                                                                                                                               
  No                                                           144     57 (39.6)       1.10 (0.61‐1.98)      .761                                                                
  Yes                                                          67      28 (41.8)                                                                                                

PVE, portal vein embolization; S1, caudate lobe; S2/3, left lateral section.

Including steatosis, fibrosis, and sinusoidal obstruction syndrome.

Including resections of portal vein, hepatic artery, and inferior vena cava.

*P* \< .05.

John Wiley & Sons, Ltd

###### 

Univariate and multivariate analyses of variables predicting disease‐free survival after right trisectionectomy

  Variables                              Total n = 195[a](#ags312292-note-0009){ref-type="fn"}   3‐y DFS (%)   MST (months)   Univariate                                        Multivariate       
  -------------------------------------- ------------------------------------------------------- ------------- -------------- ------------------------------------------------- ------------------ -----------------------------------------------
  Preoperative variables                                                                                                                                                                           
  Gender                                                                                                                                                                                           
  Female                                 80                                                      25.1          13.0           .561                                                                  
  Male                                   115                                                     27.6          15.4                                                                                
  Age                                                                                                                                                                                              
  ≤70 y                                  157                                                     26.1          13.1           .348                                                                  
  \>70 y                                 38                                                      28.2          14.6                                                                                
  Preoperative PVE                                                                                                                                                                                 
  No PVE                                 182                                                     28.0          13.9           .030[\*](#ags312292-note-0010){ref-type="fn"}     1.22 (0.59‐2.51)   .589
  PVE                                    13                                                      0.0           7.5                                                                                 
  Preoperative chemotherapy                                                                                                                                                                        
  No                                     111                                                     31.4          18.5           .029[\*](#ags312292-note-0010){ref-type="fn"}     1.23 (0.87‐1.74)   .246
  Yes                                    84                                                      19.6          11.0                                                                                
  Neoadjuvant chemotherapy                                                                                                                                                                         
  No                                     183                                                     30.0          17.6           .076                                                                  
  Yes                                    12                                                      21.6          13.8                                                                                
  Size of largest tumor                                                                                                                                                                            
  ≤100 mm                                158                                                     25.9          13.3           .436                                                                  
  \>100 mm                               37                                                      28.9          18.9                                                                                
  No. of tumors                                                                                                                                                                                    
  Solitary                               42                                                      50.5          37.0           \<.001[\*](#ags312292-note-0010){ref-type="fn"}   1.99 (1.24‐3.20)   .005[\*](#ags312292-note-0010){ref-type="fn"}
  Multiple                               153                                                     19.9          12.4                                                                                
  Type of liver metastasis                                                                                                                                                                         
  Synchronous                            107                                                     23.0          13.3           .436                                                                  
  Metachronous                           88                                                      30.3          13.1                                                                                
  Intra‐ and postoperative variables                                                                                                                                                               
  S1 resection                                                                                                                                                                                     
  No                                     174                                                     28.3          14.6           .033[\*](#ags312292-note-0010){ref-type="fn"}     1.05 (0.59‐1.85)   .881
  Yes                                    21                                                      11.0          7.4                                                                                 
  S2/3 partial resection                                                                                                                                                                           
  No                                     119                                                     33.5          22.6           \<.001[\*](#ags312292-note-0010){ref-type="fn"}   1.40 (0.98‐1.99)   .065
  Yes                                    76                                                      15.3          10.5                                                                                
  Extra bile duct resection                                                                                                                                                                        
  No                                     185                                                     26.3          13.3           .569                                                                  
  Yes                                    10                                                      30.0          9.9                                                                                 
  Lymphadenectomy                                                                                                                                                                                  
  No                                     182                                                     24.9          13.3           .448                                                                  
  Yes                                    13                                                      46.2          12.1                                                                                
  Other organ resection                                                                                                                                                                            
  No                                     167                                                     28.6          15.4           .015[\*](#ags312292-note-0010){ref-type="fn"}     134 (0.84‐2.12)    .218
  Yes                                    28                                                      13.6          6.9                                                                                 
  Portal vein resection                                                                                                                                                                            
  No                                     189                                                     26.6          13.6           .278                                                                  
  Yes                                    6                                                       20.8          9.9                                                                                 
  Hepatic artery resection                                                                                                                                                                         
  No                                     193                                                     26.2          13.3           .855                                                                  
  Yes                                    2                                                       0.5           9.9                                                                                 
  IVC resection                                                                                                                                                                                    
  No                                     187                                                     26.8          13.6           .257                                                                  
  Yes                                    8                                                       18.8          9.9                                                                                 
  Pringle\'s maneuver                                                                                                                                                                              
  No                                     66                                                      29.3          16.7           .401                                                                  
  Yes                                    129                                                     25.1          13.1                                                                                
  Total hepatic vascular exclusion                                                                                                                                                                 
  No                                     185                                                     27.8          14.6           .001[\*](#ags312292-note-0010){ref-type="fn"}     3.13 (1.46‐6.73)   .003[\*](#ags312292-note-0010){ref-type="fn"}
  Yes                                    10                                                      0.0           6.3                                                                                 
  Allogenic red blood cell transfusion                                                                                                                                                             
  No                                     159                                                     26.5          14.7           .575                                                                  
  Yes                                    36                                                      26.3          12.4                                                                                
  Fresh frozen plasma transfusion                                                                                                                                                                  
  No                                     134                                                     23.7          13.0           .376                                                                  
  Yes                                    61                                                      31.8          14.5                                                                                
  Postoperative complications                                                                                                                                                                      
  No                                     126                                                     26.9          13.3           .556                                                                  
  Yes                                    69                                                      25.8          13.6                                                                                
  Histological variables                                                                                                                                                                           
  Tumor histological grade                                                                                                                                                                         
  Well differentiated                    17                                                      25.5          21.6           .970                                                                  
  Moderate/poorly differentiated         155                                                     28.8          13.3                                                                                
  Margin status                                                                                                                                                                                    
  R0                                     114                                                     34.2          21.6           \<.001[\*](#ags312292-note-0010){ref-type="fn"}   1.60 (1.11‐2.29)   .012[\*](#ags312292-note-0010){ref-type="fn"}
  R1                                     81                                                      15.2          7.8                                                                                 
  Hepatic parenchymal histology                                                                                                                                                                    
  Steatosis                                                                                                                                                                                        
  No                                     141                                                     26.0          13.9           .859                                                                  
  Yes                                    54                                                      28.4          11.6                                                                                
  Fibrosis                                                                                                                                                                                         
  No                                     189                                                     26.1          13.3           .687                                                                  
  Yes                                    6                                                       44.4          24.4                                                                                
  Sinusoidal obstruction syndrome                                                                                                                                                                  
  No                                     177                                                     27.4          14.5           .224                                                                  
  Yes                                    18                                                      18.1          7.8                                                                                 

CI, confidence interval; DFS, disease‐free survival; IVC, inferior vena cava; MST, median survival time; PVE, portal vein embolization; RR, risk ratio; S1, caudate lobe; S2/3, left lateral section.

Excluding 16 patients who died within 90 d after operation.

*P* \< .05.

John Wiley & Sons, Ltd

###### 

Univariate and multivariate analyses of variables predicting disease‐specific survival after right trisectionectomy

  Variables                              Total n = 195[a](#ags312292-note-0012){ref-type="fn"}   5‐y DSS (%)       MST (months)   Univariate                                        Multivariate       
  -------------------------------------- ------------------------------------------------------- ------------- --- -------------- ------------------------------------------------- ------------------ -------------------------------------------------
  Preoperative variables                                                                                                                                                                               
  Gender                                                                                                                                                                                               
  Female                                 80                                                      37.5              36.6           .999                                                                  
  Male                                   115                                                     38.1              41.7                                                                                
  Age                                                                                                                                                                                                  
  ≤70 y                                  157                                                     39.0              39.9           .380                                                                  
  \>70 y                                 38                                                      31.5              38.1                                                                                
  Preoperative PVE                                                                                                                                                                                     
  No PVE                                 182                                                     39.1              40.2           .009[\*](#ags312292-note-0013){ref-type="fn"}     1.74 (0.76‐3.97)   .190
  PVE                                    13                                                      0.0               24.6                                                                                
  Preoperative chemotherapy                                                                                                                                                                            
  No                                     111                                                     44.0              43.9           .043[\*](#ags312292-note-0013){ref-type="fn"}     1.20 (0.83‐1.74)   .338
  Yes                                    84                                                      27.5              36.7                                                                                
  Neoadjuvant chemotherapy                                                                                                                                                                             
  No                                     183                                                     38.4              41.9           .065                                                                  
  Yes                                    12                                                      32.0              35.0                                                                                
  Size of largest tumor                                                                                                                                                                                
  ≤100 mm                                158                                                     36.2              39.1           .231                                                                  
  \>100 mm                               37                                                      42.9              43.8                                                                                
  No. of tumor                                                                                                                                                                                         
  Solitary                               42                                                      64.6              204.2          .001[\*](#ags312292-note-0013){ref-type="fn"}     2.95 (1.68‐5.20)   \<.001[\*](#ags312292-note-0013){ref-type="fn"}
  Multiple                               153                                                     30.0              32.8                                                                                
  Type of liver metastasis                                                                                                                                                                             
  Synchronous                            107                                                     36.7              39.9           .678                                                                  
  Metachronous                           88                                                      38.9              39.1                                                                                
  Intra‐ and postoperative variables                                                                                                                                                                   
  S1 resection                                                                                                                                                                                         
  No                                     174                                                     39.0              40.2           .042[\*](#ags312292-note-0013){ref-type="fn"}     1.21 (0.64‐2.29)   .557
  Yes                                    21                                                      28.1              26.4                                                                                
  S2/3 partial resection                                                                                                                                                                               
  No                                     119                                                     42.1              43.8           .023[\*](#ags312292-note-0013){ref-type="fn"}     0.98 (0.67‐1.42)   .905
  Yes                                    76                                                      30.8              31.8                                                                                
  Extra bile duct resection                                                                                                                                                                            
  No                                     185                                                     38.3              39.7           .702                                                                  
  Yes                                    10                                                      18.8              28.8                                                                                
  Lymphadenectomy                                                                                                                                                                                      
  No                                     182                                                     35.9              39.1           .222                                                                  
  Yes                                    13                                                      66.7              79.8                                                                                
  Other organ resection                                                                                                                                                                                
  No                                     167                                                     38.0              39.7           .344                                                                  
  Yes                                    28                                                      38.8              48.6                                                                                
  Portal vein resection                                                                                                                                                                                
  No                                     189                                                     39.0              39.6           .195                                                                  
  Yes                                    6                                                       0.0               39.7                                                                                
  Hepatic artery resection                                                                                                                                                                             
  No                                     193                                                     37.6              39.6           .456                                                                  
  Yes                                    2                                                       50.0              48.6                                                                                
  IVC resection                                                                                                                                                                                        
  No                                     187                                                     38.5              39.9           .111                                                                  
  Yes                                    8                                                       17.5              39.7                                                                                
  Pringle\'s maneuver                                                                                                                                                                                  
  No                                     66                                                      36.6              37.8           .717                                                                  
  Yes                                    129                                                     38.1              40.0                                                                                
  Total hepatic vascular exclusion                                                                                                                                                                     
  No                                     185                                                     39.1              40.0           .009[\*](#ags312292-note-0013){ref-type="fn"}     3.77 (1.73‐8.20)   .001[\*](#ags312292-note-0013){ref-type="fn"}
  Yes                                    10                                                      11.3              16.7                                                                                
  Allogenic red blood cell transfusion                                                                                                                                                                 
  No                                     159                                                     37.2              39.7           .581                                                                  
  Yes                                    36                                                      39.5              38.5                                                                                
  Fresh frozen plasma transfusion                                                                                                                                                                      
  No                                     134                                                     36.0              37.8           .651                                                                  
  Yes                                    61                                                      41.1              42.7                                                                                
  Postoperative complications                                                                                                                                                                          
  No                                     126                                                     37.1              39.1           .990                                                                  
  Yes                                    69                                                      39.2              40.0                                                                                
  Histological variables                                                                                                                                                                               
  Tumor histological grade                                                                                                                                                                             
  Well differentiated                    17                                                      37.6              39.7           .635                                                                  
  Moderate/poorly differentiated         155                                                     40.3              41.5                                                                                
  Margin status                                                                                                                                                                                        
  R0                                     114                                                     47.7              50.7           \<.001[\*](#ags312292-note-0013){ref-type="fn"}   1.92 (1.31‐2.81)   .001[\*](#ags312292-note-0013){ref-type="fn"}
  R1                                     81                                                      22.9              20.8                                                                                
  Hepatic parenchymal histology                                                                                                                                                                        
  Steatosis                                                                                                                                                                                            
  No                                     141                                                     36                38.5           .641                                                                  
  Yes                                    54                                                      42.6              43.9                                                                                
  Fibrosis                                                                                                                                                                                             
  No                                     189                                                     37.7              39.6           .949                                                                  
  Yes                                    6                                                       40                58.3                                                                                
  Sinusoidal obstruction syndrome                                                                                                                                                                      
  No                                     177                                                     38.6              40             .339                                                                  
  Yes                                    18                                                      27.6              36.7                                                                                

CI, confidence interval; DSS, disease‐specific survival; IVC, inferior vena cava; MST, median survival time; PVE, portal vein embolization; RR, risk ratio; S1, caudate lobe; S2/3, left lateral section.

Excluding 16 patients who died within 90 d after operation.

*P* \< .05.

John Wiley & Sons, Ltd

3.4. Changes in outcomes over time and redo‐surgery for recurrence {#ags312292-sec-0019}
------------------------------------------------------------------

To evaluate the impact of the learning curve and changes over the study period, patients were divided into three operative experience periods: first (n = 70; 33.2%), second (n = 70; 33.2%), and third (n = 71; 33.6%) period as described in Table [5](#ags312292-tbl-0005){ref-type="table"}. Median DFS was 33.8, 26.8 and 25.5 months from the first to the third period, *P* = .774. Frequency of further surgery for recurrent disease after RT increased steadily over time. Of the 211 patients who underwent RHT, 152 patients (72.0%) had disease recurrence, of whom 38 (25.0%) were eligible for further surgery. Eleven patients (7.2%) underwent a second repeat surgery, six (3.9%) patients had a third surgery and one (0.7%) patient a fourth repeat surgery with curative intent. Median interval from RHT to further surgery was 13.3 months; there was a median of 38.8 months to the second, 43.6 to the third, and 129.6 to the fourth surgery. Mortality after further surgery was zero. One or more redo liver resections were carried out in 31 patients (20.4%). One or more pulmonary surgeries including radiofrequency ablation were done in seven patients (4.6%). Two patients (1.3%) underwent other surgery for recurrent lesions (para‐aortic lymph node extirpation and pancreaticoduodenectomy). Of the 152 patients with recurrence, 114 patients (75%) had palliative chemotherapy alone. Five‐and 10‐year DSS were 58.1% and 25.8%, respectively, with a median DSS time of 70.5 months for the patients who underwent further surgery for recurrence and 15.6% and 2.7%, respectively, with a median DSS time of 26.4 months for those who had palliative treatment only (*P* \< .001) (Figure [1](#ags312292-fig-0001){ref-type="fig"}).

###### 

Changes in pre‐ and intraoperative management and postoperative outcomes according to the experience period

                                                                               Experience period, n (%)   *P*‐value                   
  ---------------------------------------------------------------------------- -------------------------- -------------- ------------ -------------------------------------------------
  Age, years (range)                                                           61 (36‐80)                 61.5 (42‐84)   63 (25‐85)   .402
  Preoperative chemotherapy                                                    18 (25.7)                  23 (32.9)      48 (67.6)    \<.001[\*](#ags312292-note-0018){ref-type="fn"}
  Preoperative PVE                                                             0 (0)                      0 (0)          13 (18.3)    \<.001[\*](#ags312292-note-0018){ref-type="fn"}
  Parenchymal liver damage                                                     7 (10.0)                   16 (22.9)      49 (69.0)    \<.001[\*](#ags312292-note-0018){ref-type="fn"}
  Steatosis                                                                    5 (7.1)                    14 (20.0)      38 (53.5)    \<.001[\*](#ags312292-note-0018){ref-type="fn"}
  Fibrosis                                                                     2 (2.9)                    3 (4.3)        1 (1.4)      .590
  Sinusoidal obstruction syndrome                                              0 (0)                      0 (0)          18 (25.4)    \<.001[\*](#ags312292-note-0018){ref-type="fn"}
  S1 resection                                                                 4 (5.7)                    7 (10.0)       14 (19.7)    .031[\*](#ags312292-note-0018){ref-type="fn"}
  S2/3 partial resection                                                       19 (27.1)                  30 (42.9)      31 (43.7)    .075
  Vascular resection[a](#ags312292-note-0015){ref-type="fn"}                   5 (7.1)                    3 (4.3)        7 (9.9)      .436
  Pringle\'s maneuver                                                          33 (47.1)                  43 (61.4)      61 (85.9)    \<.001[\*](#ags312292-note-0018){ref-type="fn"}
  Total hepatic vascular exclusion                                             9 (12.9)                   3 (4.3)        2 (2.8)      .023[\*](#ags312292-note-0018){ref-type="fn"}
  Allogenic red blood cell transfusion                                         28 (40.0)                  12 (17.1)      4 (5.6)      \<.001[\*](#ags312292-note-0018){ref-type="fn"}
  Fresh frozen plasma transfusion                                              47 (67.1)                  30 (42.9)      8 (11.3)     \<.001[\*](#ags312292-note-0018){ref-type="fn"}
  Morbidity                                                                    28 (40.0)                  33 (47.1)      24 (33.8)    .271
  Median hospital stay, days (range)[b](#ags312292-note-0016){ref-type="fn"}   11 (6‐34)                  11 (4‐139)     9 (5‐71)     .119
  90‐d mortality                                                               9 (12.9)                   5 (7.1)        2 (2.8)      .078
  Further surgery for recurrence[c](#ags312292-note-0017){ref-type="fn"}       11 (21.6)                  12 (24.0)      15 (29.4)    .645

PVE, portal vein embolization; S1, caudate lobe; S2/3, left lateral section.

Including resections of portal vein, hepatic artery, and inferior vena cava.

Excluding 15 patients who died in hospital.

51, 50, and 51 patients with recurrence in the 1st, 2nd, and 3rd periods, respectively.

*P* \< .05.

John Wiley & Sons, Ltd

![Disease‐specific survival following further surgery compared to palliative chemotherapy alone](AGS3-3-606-g001){#ags312292-fig-0001}

4. DISCUSSION {#ags312292-sec-0020}
=============

Several centers worldwide have reported their experience with RHT or LHT and extensions of RHT for a variety of indications in HPB malignancies. However, the existing evidence on this topic is scarce and limited to small numbers. Only a few studies for RHT and LHT have reported their experience in larger cohorts.[5](#ags312292-bib-0005){ref-type="ref"}, [7](#ags312292-bib-0007){ref-type="ref"}, [9](#ags312292-bib-0009){ref-type="ref"}, [13](#ags312292-bib-0013){ref-type="ref"}, [14](#ags312292-bib-0014){ref-type="ref"}, [26](#ags312292-bib-0026){ref-type="ref"}, [34](#ags312292-bib-0034){ref-type="ref"}, [35](#ags312292-bib-0035){ref-type="ref"}, [36](#ags312292-bib-0036){ref-type="ref"} This limited evidence might reflect the changing role of these demanding and extensive resections in daily HPB practice, with decreasing numbers being carried out today. This must be at least in part due to promising results for newly implemented surgical strategies such as TSH and ALPPS, along with oncological advances with better understanding of tumor biology resulting in increasing success with neoadjuvant treatment.

Extended resections have been associated with high morbidity and mortality rates.[37](#ags312292-bib-0037){ref-type="ref"} In 1988, Iwatsuki and Starzl reported their experience showing a mortality rate of 6.3% following right trisectionectomies in their series.[37](#ags312292-bib-0037){ref-type="ref"}

In our original report of 275 patients undergoing trisectionectomies including various HPB malignancies, postoperative morbidity was 41%.[26](#ags312292-bib-0026){ref-type="ref"} Thirty‐day and 90‐day mortality rates were 7% and 8%, respectively.[26](#ags312292-bib-0026){ref-type="ref"} In this up‐to‐date study, morbidity among all RHT trisectionectomies carried out was 40.3%, and 30‐day and 90‐day mortality rates were 7.1% and 7.6%, respectively, following this procedure. In a separate analysis assessing morbidity and mortality rates over time, we have been able to show a tendency for reduced morbidity and mortality. These results have been confirmed by other groups.[36](#ags312292-bib-0036){ref-type="ref"} In their series of RHT, Matsumoto et al showed a morbidity rate of 27% and a mortality rate of 0%.[36](#ags312292-bib-0036){ref-type="ref"} These results seem to be comparable with outcomes following modern approaches such as TSH or ALPPS.[24](#ags312292-bib-0024){ref-type="ref"}

In extensive liver resections, the size of FLR may have a crucial impact on postoperative morbidity and mortality. In general, 3%‐5% of patients may develop liver failure following liver resection. In the present study, the incidence of transient liver failure was 12% (mainly grade A or B according to the International Study Group of Liver Surgery) and reflects the magnitude of surgery. Controversy exists about the amount of liver volume essential to prevent liver failure following these operations. After RHT, FLR is variable but approximately 15%‐30% of the total liver volume is preserved. Recent studies have shown that FLR of less than 25%‐30% is predictive of hepatic dysfunction.[38](#ags312292-bib-0038){ref-type="ref"} Therefore, the use of PVE before trisectionectomy has been advocated to decrease postoperative morbidity and mortality and make these operations safer.[39](#ags312292-bib-0039){ref-type="ref"} When assessing PVE in the preoperative setting of right trisectionectomies, several studies have shown the importance of embolizing segment 4 to achieve sufficient hypertrophy.[40](#ags312292-bib-0040){ref-type="ref"}, [41](#ags312292-bib-0041){ref-type="ref"} Indeed, this has become part of our routine for patients with CRLM after chemotherapy before RHT and, in recent years, we have not experienced any postoperative mortality.

In the present study, multivariate analysis identified additional organ resection at the time of RHT and perioperative ARBC transfusion as independent predictors of postoperative morbidity. In this series, concomitant organ resection was carried out in 32 patients (15.2%) of the cohort. The diaphragm or large bowel was resected most frequently. The inferior outcome following multi‐organ resection most likely reflects a poor and aggressive tumor biology as well as advanced tumor stage.

In other studies, intraoperative blood loss and concomitant blood transfusion were identified as independent risk factors influencing morbidity, mortality and DSS.[9](#ags312292-bib-0009){ref-type="ref"}, [42](#ags312292-bib-0042){ref-type="ref"}, [43](#ags312292-bib-0043){ref-type="ref"}, [44](#ags312292-bib-0044){ref-type="ref"} This measurement indirectly displays the extent and quality of the surgery itself. A median of 4 units [1](#ags312292-bib-0001){ref-type="ref"}, [2](#ags312292-bib-0002){ref-type="ref"}, [3](#ags312292-bib-0003){ref-type="ref"}, [4](#ags312292-bib-0004){ref-type="ref"}, [5](#ags312292-bib-0005){ref-type="ref"}, [6](#ags312292-bib-0006){ref-type="ref"}, [7](#ags312292-bib-0007){ref-type="ref"}, [8](#ags312292-bib-0008){ref-type="ref"}, [9](#ags312292-bib-0009){ref-type="ref"}, [10](#ags312292-bib-0010){ref-type="ref"}, [11](#ags312292-bib-0011){ref-type="ref"}, [12](#ags312292-bib-0012){ref-type="ref"}, [13](#ags312292-bib-0013){ref-type="ref"}, [14](#ags312292-bib-0014){ref-type="ref"}, [15](#ags312292-bib-0015){ref-type="ref"}, [16](#ags312292-bib-0016){ref-type="ref"}, [17](#ags312292-bib-0017){ref-type="ref"}, [18](#ags312292-bib-0018){ref-type="ref"}, [19](#ags312292-bib-0019){ref-type="ref"}, [20](#ags312292-bib-0020){ref-type="ref"}, [21](#ags312292-bib-0021){ref-type="ref"}, [22](#ags312292-bib-0022){ref-type="ref"}, [23](#ags312292-bib-0023){ref-type="ref"}, [24](#ags312292-bib-0024){ref-type="ref"}, [25](#ags312292-bib-0025){ref-type="ref"}, [26](#ags312292-bib-0026){ref-type="ref"}, [27](#ags312292-bib-0027){ref-type="ref"}, [28](#ags312292-bib-0028){ref-type="ref"}, [29](#ags312292-bib-0029){ref-type="ref"}, [30](#ags312292-bib-0030){ref-type="ref"}, [31](#ags312292-bib-0031){ref-type="ref"}, [32](#ags312292-bib-0032){ref-type="ref"}, [33](#ags312292-bib-0033){ref-type="ref"}, [34](#ags312292-bib-0034){ref-type="ref"}, [35](#ags312292-bib-0035){ref-type="ref"}, [36](#ags312292-bib-0036){ref-type="ref"}, [37](#ags312292-bib-0037){ref-type="ref"}, [38](#ags312292-bib-0038){ref-type="ref"}, [39](#ags312292-bib-0039){ref-type="ref"}, [40](#ags312292-bib-0040){ref-type="ref"} of red blood cells was transfused. Nearly 80% of patients did not require perioperative transfusion and there was a consistent decline in the need for transfusion over time. This may reflect improved surgical and anesthetic techniques as well as more conservative transfusion over time with higher thresholds for transfusion.

Our study further identified multiple tumors and R1 resections as independent predictors for recurrence and poor survival following liver resection for CRLM.[45](#ags312292-bib-0045){ref-type="ref"}, [46](#ags312292-bib-0046){ref-type="ref"}, [47](#ags312292-bib-0047){ref-type="ref"}, [48](#ags312292-bib-0048){ref-type="ref"}, [49](#ags312292-bib-0049){ref-type="ref"}, [50](#ags312292-bib-0050){ref-type="ref"} This corresponds to results of other studies.[51](#ags312292-bib-0051){ref-type="ref"}, [52](#ags312292-bib-0052){ref-type="ref"}, [53](#ags312292-bib-0053){ref-type="ref"} Sasaki et al clearly identified tumor size and number of CRLM as prognostic markers predicting outcome following resection of CRLM.[54](#ags312292-bib-0054){ref-type="ref"} Furthermore, our study identified TVE as an independent risk factor for poor survival. This might be due to advanced tumor stage when TVE was applied with invasion to the hepatocaval confluence or IVC. The radicality of surgery required, is associated with an increased potential for postoperative complications, this might be due to the fact that this type of surgery can potentially cause significant hemodynamic instability.[55](#ags312292-bib-0055){ref-type="ref"}, [56](#ags312292-bib-0056){ref-type="ref"}, [57](#ags312292-bib-0057){ref-type="ref"}

Furthermore, in animal studies, TVE has been clearly linked to accelerated growth of hepatic micrometastases.[50](#ags312292-bib-0050){ref-type="ref"}, [58](#ags312292-bib-0058){ref-type="ref"} Indeed, nine out of 14 (64.3%) patients who required TVE had an R1 resection. In a separate analysis, a decrease of TVE over time was noted, again showing the increased experience with a higher caseload.

Repeat hepatic resection is technically challenging, with longer operative time than the initial surgery because of adhesions, altered anatomy, and fragile liver parenchyma as a result of chemotherapy, and it has rarely been reported following RHT.[15](#ags312292-bib-0015){ref-type="ref"}, [59](#ags312292-bib-0059){ref-type="ref"}, [60](#ags312292-bib-0060){ref-type="ref"}, [61](#ags312292-bib-0061){ref-type="ref"}, [62](#ags312292-bib-0062){ref-type="ref"}, [63](#ags312292-bib-0063){ref-type="ref"} However, in this series, repeat resection showed better 5‐ and 10‐year DSS of 58.1% and 25.8%, respectively, compared to DSS of 15.6% and 2.7% in patients undergoing palliative chemotherapy only. Furthermore, there was no postoperative mortality among patients who underwent repeat resections and none developed liver failure in the further postoperative course.

A limitation of the present study is the incomplete data on chemotherapy. As a result of this limitation, a detailed analysis of the role of chemotherapy in this treatment algorithm was not possible. Only a relatively small proportion of patients received neoadjuvant therapy for downsizing, but the proportion in whom downsizing strategies failed was not captured in the data set.

5. CONCLUSION {#ags312292-sec-0021}
=============

Left hepatic trisectionectomy and RHT are technically demanding liver resections with a high risk for perioperative morbidity and, in the past, also mortality. Our data show these risks are reducing with experience, better patient selection, and the more liberal use of PVE. LHT and RHT remain relevant for many situations but innovation in surgery and neoadjuvant treatments inevitably mean that the role of these challenging operations is decreasing.
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